Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGSWW) Equity Average (2020 - 2025)

GeneDx Holdings has reported Equity Average over the past 6 years, most recently at $300.2 million for Q4 2025.

  • Quarterly results put Equity Average at $300.2 million for Q4 2025, up 33.51% from a year ago — trailing twelve months through Dec 2025 was $300.2 million (up 33.51% YoY), and the annual figure for FY2025 was $276.7 million, up 16.94%.
  • Equity Average for Q4 2025 was $300.2 million at GeneDx Holdings, up from $284.7 million in the prior quarter.
  • Over the last five years, Equity Average for WGSWW hit a ceiling of $599.3 million in Q3 2022 and a floor of -$544.2 million in Q2 2021.
  • Median Equity Average over the past 5 years was $271.2 million (2023), compared with a mean of $212.3 million.
  • Biggest five-year swings in Equity Average: soared 783.01% in 2022 and later tumbled 54.08% in 2023.
  • GeneDx Holdings' Equity Average stood at $389.6 million in 2021, then rose by 4.6% to $407.5 million in 2022, then crashed by 40.83% to $241.1 million in 2023, then decreased by 6.74% to $224.9 million in 2024, then soared by 33.51% to $300.2 million in 2025.
  • The last three reported values for Equity Average were $300.2 million (Q4 2025), $284.7 million (Q3 2025), and $267.3 million (Q2 2025) per Business Quant data.